Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dormouse BV currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is located in 1 distinct art unit, indicating a concentrated prosecution effort for the company's current intellectual property in 1 specialized division of the patent office.
The portfolio's prosecution is handled by 1 distinct examiner, HOFFMAN, SUSAN COE. This means that 1 individual is responsible for reviewing the company's active application, which ensures that the prosecution of the matter is managed by 1 person throughout the process.
As the busiest examiner, HOFFMAN, SUSAN COE is responsible for 1 pending office action. Because this single examiner oversees 1 out of 1 total pending matters, the company's entire active prosecution landscape is currently dependent on the review and timeline of this 1 individual at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713294 | ANTI-AGEING SUPPLEMENT | HOFFMAN, SUSAN COE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18713294 | ANTI-AGEING SUPPLEMENT | HOFFMAN, SUSAN COE | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713294 | ANTI-AGEING SUPPLEMENT | HOFFMAN, SUSAN COE | 1663 | §101§102§103 | Non-Final OA | — | Pending | May 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDormouse BV has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susan Coe Hoffman has the most, with 1 of Dormouse BV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
